Favnox Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 05-07-2024
- Paid Up Capital ₹ 0.10 M
as on 05-07-2024
- Company Age 4 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -39.26%
(FY 2022)
- Profit 167.50%
(FY 2022)
- Ebitda 192.56%
(FY 2022)
- Net Worth 95.24%
(FY 2022)
- Total Assets -24.36%
(FY 2022)
About Favnox Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sushant Gantayata, Avanti Malve, and Shreenath Panigrahy serve as directors at the Company.
- CIN/LLPIN
U24239TG2020PTC143312
- Company No.
143312
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Aug 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Favnox Pharmaceuticals Private Limited offer?
Favnox Pharmaceuticals Private Limited offers a wide range of products and services, including TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Pain Relief Drugs & Pharmaceuticals, Antipyretic Medication, Common Disease Medicines, Injectable Products, Pharma Ingredients & Raw Materials, Anti Infective API, Graphic Design & Animation Services, Designing Services.
Who are the key members and board of directors at Favnox Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sushant Gantayata | Director | 21-Aug-2022 | Current |
Avanti Malve  | Director | 29-Aug-2020 | Current |
| Shreenath Panigrahy | Director | 29-Aug-2020 | Current |
Financial Performance of Favnox Pharmaceuticals.
Favnox Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 39.26% decrease. The company also saw a substantial improvement in profitability, with a 167.5% increase in profit. The company's net worth Soared by an impressive increase of 95.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Favnox Pharmaceuticals?
In 2022, Favnox Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Favnox Pharmaceuticals?
Favnox Pharmaceuticals has a workforce of 0 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Favnox Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Favnox Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
